Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-04-19
    E.g., 2018-04-19

Articles

Pages

26458 items
12:19 PM, Apr 13, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Virta reports data for continuous care intervention strategy for Type II diabetes

Data reported in Diabetes Therapy showed that the Virta Treatment intervention strategy from Virta Health Corp. (San Francisco, Calif.) safely reduced HbA1c, body weight and diabetes medication use in an open-label study in 349 Type...
10:59 AM, Apr 13, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Ocugen reports Phase II data for dry eye disease candidate

Ocugen Inc. (Malvern, Pa.) reported data from a Phase II trial showing that dry eye disease candidate OCU310 met the primary endpoint of tolerability over a 12-week period. The company said the trial was not...
10:59 AM, Apr 13, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Valneva reports Phase I data for Lyme disease vaccine candidate

Valneva SE (Euronext Paris:VLA; VSE:VLA) reported interim data from a Phase I trial in 179 healthy volunteers ages 18-40 showing that Lyme disease candidate VLA15 (VLA15-101) met the primary endpoint by achieving a "favorable" safety...
10:59 AM, Apr 13, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Leap reports Phase I data from monotherapy arm of esophageal cancer trial

Leap Therapeutics Inc. (NASDAQ:LPTX) reported data from 16 patients with advanced esophagogastric cancer in the Phase I P102 trial showing that DKN-01 as monotherapy led to two partial responses, plus five cases of stable disease....
10:58 AM, Apr 13, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Wilson reports 72-week data Wilson’s disease candidate

Wilson Therapeutics AB (SSE:WTX) reported data from 20 evaluable patients with Wilson’s disease in the extension portion of the 24-week Phase II WTX101-201 trial showing that once-daily oral Decuprate bis-choline tetrathiomolybdate (WTX101) controlled mean nonceruloplasmin-bound...
6:39 AM, Apr 13, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Adynxx planning Phase III for pain candidate despite Phase II miss

Adynxx Inc. (San Francisco, Calif.) said that although brivoligide (AYX1) missed the primary endpoint in the Phase II ADYX-004 trial to treat postsurgical pain, the company still sees a path to Phase III based on...
6:39 AM, Apr 13, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

CymaBay reports additional Phase II data for seladelpar

CymaBay Therapeutics Inc. (NASDAQ:CBAY) reported additional interim data from a Phase II trial of seladelpar (MBX-8025) to treat primary biliary cholangitis (PBC) in patients who had an inadequate response or intolerance to ursodeoxycholic acid. The...
6:38 AM, Apr 13, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Spectrum reports updated Phase II data for poziotinib in NSCLC

Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) reported updated data from a Phase II trial showing that poziotinib (HM781-36B) led to a confirmed objective response rate (ORR) of 64% in 11 evaluable non-small cell lung cancer (NSCLC) patients...
6:38 AM, Apr 13, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Selecta reports additional Phase II data for gout combo

Selecta Biosciences Inc. (NASDAQ:SELB) reported additional data from an open-label, U.S. Phase II trial of lead candidate SEL-212 to treat chronic, severe gout. SEL-212 is a non-immunogenic therapy comprising pegsiticase (SEL-037), a pegylated uricase, co-administered...
6:37 AM, Apr 13, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Patient deaths reported in Tecentriq, Cotellic combo arm of Phase II mCRC trial

Roche (SIX:ROG; OTCQX:RHHBY) said it temporarily halted recruitment in the Phase II MODUL trial to treat metastatic colorectal cancer (mCRC) following four deaths, including a case of treatment-related cardiogenic shock, in a cohort of patients...

Pages